Oxford Immunotec to Present at the Jefferies 2016 London Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., 2016-11-02 19:28 CET (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Peter Wrighton-Smith, Chief Executive Officer, will present at the Jefferies 2016 London Healthcare Conference on Wednesday, November 16, 2016, at 1:20 p.m. GMT (8:20 a.m. ET).
A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website atwww.oxfordimmunotec.com. A webcast replay will be available approximately 24 hours after the live presentation and will be archived on the website for approximately 60 days.
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company’s first product is the TSPOT®.TBtest, which is used to test for tuberculosis infection. The T-SPOT.TBtest has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The company’s second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. The T-SPOT.CMVtest and the T-SPOT.PRTtest are part of the Company’s third product line focused on the transplantation market. In addition to these three product lines, the Company has additional active development programs in other immune-regulated conditions. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found atwww.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
For Media Inquiries:
Tel: +44 1235 442796
For Investor Inquiries:
Chief Financial Officer
Tel: +1 (508) 573-9953
Tel: +1 (443) 213-0501
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Percona22.2.2018 09:02 | pressemeddelelse
Percona Unveils Full Conference Session Schedule for the Annual Percona Live Open Source Database Conference 2018
Taconic Biosciences21.2.2018 19:15 | pressemeddelelse
Taconic Biosciences Announces the Formation of Scientific Advisory Board
TrueCommerce21.2.2018 16:01 | pressemeddelelse
TrueCommerce Dynamics 365 Solution Featured on Microsoft AppSource
Cisco21.2.2018 14:01 | pressemeddelelse
Cisco 2018 Annual Cybersecurity Report Reveals Security Leaders Rely on and Invest in Automation, Machine Learning and Artificial Intelligence to Defend Against Threats
Appian Corporation21.2.2018 13:31 | pressemeddelelse
Appian Corporation : Banco Santander Selects Appian
Inspiration Mining Corporation20.2.2018 21:37 | pressemeddelelse
Inspiration Mining to File a Complaint with OSC Against Stockwatch
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum